Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Kempinski Hotel River Park
Popular Articles

American Lung Association Experts To Testify At EPA Public Hearings Urging Stronger Nitrogen Dioxide Air Pollution Standards
The American Lung Association will tell the Environmental Protection Agency (EPA) at a public hearing today to adopt even stronger, health-based national air quality standards for nitrogen dioxide (NO2) than what the agency proposed. Lung Association leadership and healthy air advocates will call for tighter standards at the hearing that begins at 9:00 AM at the EPA Potomac Yard Conference Center located at 1 Potomac Yard, 2777 South Crystal Drive in Arlington, Va. Mary Partridge, American Lung Association National Board Chair, is scheduled to speak at 10:15 AM. The hearing will conclude at 9:00 PM.
generic viagra online
Research Carried Out In Mice Will Contribute To The Study Of Hereditary Diseases That Lead To Blindness
Researchers of the University of Granada (Spain) have used a technique consisting of the induction of neuronal degeneration neuronal for intense light exposure in the mouse"s retina that will be helpful for the study of retinitis pigmentosa (RP), a group of hereditary diseases which lead to blindness and affect more than one million persons a year all over the world. In addition, the results of this research work could be very useful for the detection of new factors or molecules originated by microglial cells and related to degenerative processes of the retina.
News of the day
UAW To Accept Up To 20% Of GM Stock; Agrees To Concessions On Retiree Health Care Obligations, Labor Rules
United Auto Workers leaders on Tuesday agreed to accept up to 20% of General Motors stock, as well as concessions on labor rules and retiree health care obligations, as the automaker faces a June 1 deadline to restructure or seek bankruptcy protection, the Detroit News reports (Aguilar/Shepardson, Detroit News, 5/27). Under the deal, the voluntary employees" beneficiary association would receive 17.5% of common GM stock, $6.5 billion of preferred shares, a $2.5 billion note and warrants equal to 2.5% of GM"s stock (Reuters/USA Today, 5/27). In addition, the VEBA would receive $585 million annually in interest income on its preferred stock (Detroit News, 5/27). Another concession included in the tentative deal is the elimination of dental, vision and some prescription drug coverage for hourly retirees (Shepardson/Aguilar, Detroit News, 5/26). UAW also would hold a seat on the GM board of directors (Cho et al., Washington Post, 5/27).Because of a proposed deal announced earlier this month, the Treasury Department and UAW, together, are to own 89% of GM"s stock, meaning that if the UAW-GM deal is approved, the Treasury would own about a 70% share of GM"s stock (Detroit News, 5/26). Current bondholders would hold about a 10% stake in the company (Washington Post, 5/27). The remaining 1% would be held by existing shareholders (Detroit News, 5/26).The total 20% is about half of what was anticipated (Higgins, Detroit Free Press, 5/26). The "significant concessions" made by UAW, which was eligible to receive up to 39% of GM"s equity through the VEBA, "could mean that [GM] is attempting to appease unsecured bondholders, who charged that the UAW was getting a better deal," according to the News (Detroit News, 5/27). UAW said the revised agreement with GM was necessary for the automaker to survive, but the deal will leave hundreds of thousands of GM retirees paying higher out-of-pocket medical expenses, the Wall Street Journal reports (Stoll et al., Wall Street Journal, 5/27).UAW members are scheduled to vote on the agreement on Wednesday and Thursday (Detroit News, 5/26). However, "[e]ven with UAW approval, GM is still likely to file for bankruptcy, since bondholders are unlikely to swallow deep concessions," according to the News (Detroit News, 5/27).
Cardiovascular

Dr. David B. Samadi Introduces New Prostate Cancer Care Center For Robotic Surgery Patients At Mount Sinai Medical Center

The Mount Sinai Medical Center has a new re center for prostate cancer treatment. Led by David B. Samadi, M.D., Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology, the new state-of-the-art facility at 625 Madison Avenue in New York City specializes in pre- and post-surgery care for patients who undergo a robotic prostatectomy at Mount Sinai"s main campus. It also provides expertise in the treatment of other urologic cancers, including bladder and kidney. A multilingual staff offers assistance with patient travel arrangements, accommodations, and translation services when required. "The care that patients receive before and after undergoing robotic surgery is as crucial to their recovery as the procedure itself," said Dr. Samadi. "At our new facility, patients are welcomed by a caring and compassionate staff that is ready to answer their questions on a variety of issues, including concerns about their continence, kegel exercises and sexual health. There"s an ample array of learning materials and brochures, and high-definition TV screens play educational tapes, presentations and DVDs. By the time I see my patients, they are at ease, well-informed and ready to take the next steps in their prostate care. Once they undergo robotic surgery at Mount Sinai"s main campus, our new facility offers them the additional care that they need on their road to recovery." Also known as Robotic Assisted Laparoscopic Prostatectomy, robotic prostatectomy is a minimally invasive type of prostate cancer surgery that utilizes a robotic surgical unit called the da Vinci system, manufactured by Intuitive Surgical. This prostate surgery is a revolutionary and advanced procedure that profoundly reduces blood loss, pain, recovery time, hospital stays, trauma to surrounding tissue and the drastically reduced side effects of other treatments such as incontinence and sexual dysfunction. "Our goal," Dr. Samadi says, "is not just survival, but to improve the patients" quality of life." One of the nation"s leading urologic oncologists, specializing in robotics and minimally invasive surgery for prostate cancer, Dr. Samadi has achieved great success treating more than 1,800 prostate cancer patients from around the world. He is one of very few urologic oncologic surgeons in the United States trained in all three primary areas of surgery -- open, laparoscopic, and robotic. Patients interested in obtaining more information about Mount Sinai"s new prostate cancer care facility and Robotic Assisted Laparoscopic Prostatectomy may call 212-241-8779 or visit, http://www.roboticoncology.com. The Mount Sinai Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009